Chief Sales Officer of AI-Media Excited to Showcase Subtitling Innovation at Upcoming IBC Broadcast Tradeshow

AI-Media Exhibits at IBC 2023

AI-Media to exhibit at IBC 2023 in Amsterdam, NE from 15-18 Sept 2023

BROOKLYN, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — AI-Media, the leader in technology-driven live captioning & subtitling, transcription, and translation solutions, is excited to announce its presence at the IBC Show 2023, scheduled to take place from 15th – 18th September in Amsterdam, NE. The event promises to be a gathering of industry experts, thought leaders, and innovative companies in the broadcast and media technology sector.

As the global leader in captioning and subtitling for the broadcast industry, AI-Media is proud to be part of this influential event. Our Chief Sales Officer, James Ward, will lead our delegation and represent our commitment to excellence in delivering cutting-edge solutions to our clients and partners.

AI-Media’s Chief Sales Officer, James Ward said:

“We are delighted to participate at the IBC show once again. This tradeshow is an exceptional platform for us to showcase our latest innovations and demonstrate how we continue to push the boundaries of what’s possible in the broadcast industry. We’re excited to engage with industry leaders, customers, and partners, and to share our vision for the future of broadcasting.”

AI-Media will be showcasing several key broadcast solutions at the event, the cornerstone of which is our AI-Powered live automatic captioning solution – LEXI. LEXI consistently delivers accuracy rates of over 98%, identifies speaker changes, uses AI to ensure captions don’t interrupt onscreen content and all at a fraction of the cost of human captions. This innovative tool is revolutionizing real-time captioning, providing a cost-effective solution that has been embraced by the world’s leading broadcasters. AI-Media will be conducting live demos at the booth to display this groundbreaking technology in action.

The recently launched AI-powered LEXI Captioning Tool Kit will also be featured at IBC2023, featuring six key solutions each designed to address different captioning needs. LEXI Tool Kit transforms content creation and captioning, offering complete end-to-end solutions for media companies, broadcasters, event producers, educational institutions, and content creators worldwide. Broadcasters can mix and match the Tool Kit components to suit their business needs, accessing solutions including captioning, translation, archiving & search and disaster recovery.

With IP video production at the forefront of innovation in the broadcasting landscape; broadcasters can look to AI-Media’s ALTA solution for their IP compatible closed captioning and subtitling encoding solution. ALTA supports global broadcast standards including SMPTE-2110, MPEG-TS inputs, and can output 2110-40, DVB subtitles, DVB TTML, DVB Teletext and SMPTE 2038. Deployable as a standalone virtual machine, a pre-packaged AMI or turnkey physical server, ALTA can fit into any production workflow. Along with effortlessly handling six languages per instance, ALTA also supports the insertion of advertising cues using SCTE-35 and SCTE-104. With ALTA, AI-Media is helping broadcasters elevate their IP video broadcasts to new heights of reach and accessibility. Also available at the booth will be our range of SDI Hardware Encoders, including our Encoder Pro (HD492) 1 RU caption encoder – now synonymous as the broadcast standard for SDI encoders.

We’re also excited to provide customers with an early look at our upgraded LEXI Translate solution, which is the next level of language accessibility within our LEXI Tool Kit. This soon to be released version boasts unmatched accuracy in real-time translation, allowing broadcasters to distribute content to a wider audience than ever before.

Join AI-Media at IBC 2023, September 15-18, RAI Amsterdam Convention Centre, Booth #5.C31. Attendees are encouraged to book a meeting with the AI-Media team to discover our range of end-to-end broadcast captioning solutions.

About AI-Media

Founded in Australia in 2003, technology company AI-Media is a global leader in live and recorded captioning, transcription and translation solutions. The company helps the world’s leading broadcasters, enterprises and government agencies ensure high accuracy, secure and cost-effective captioning via its AI-powered LEXI automatic captioning solution. LEXI captions are delivered to millions of screens worldwide via AI-Media’s range of captioning encoders and its iCap Cloud Network – the world’s largest, most secure caption delivery network. Globally, AI-Media delivers over 8 million minutes of live and recorded media monthly. AI-Media trades on the Australian Stock Exchange (ASX:AIM). For more information, please visit AI-Media.tv.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/976356bd-2ae1-4f56-89ed-437f9da454a2

Media Contact:
Fiona Habben
Senior Marketing Manager – Global
Fiona.habben@ai-media.tv

GlobeNewswire Distribution ID 8921516

“Averting the SaaS Data Apocalypse” by Simon Taylor: A Journey Through the SaaS Data Landscape

New Book is a Comprehensive Exploration of the Rising Threat to Digital Data and the Race to Protect It

Boston, Massachusetts, Sept. 13, 2023 (GLOBE NEWSWIRE) —  HYCU, Inc., the fastest growing data protection as a service company is taking a major first step as the digital world is on the brink of a catastrophe. As more companies increasingly rely on Software as a Service (SaaS) solutions, the looming SaaS data apocalypse is quickly emerging as the most significant threat to data in years. Today, Simon Taylor’s new book, Averting the SaaS Data Apocalypse,” is released to shine a light on this imminent digital threat and share real world examples of what can be done to avoid digital mayhem.

From the meteoric rise of the SaaS data apocalypse to deep dives into how leading organizations, including the Boston Red Sox, Zebra Technologies, Bain Capital, and LS Direct, have navigated these challenging waters, Taylor offers an unparalleled insight into the modern SaaS landscape.

In the book’s foreword, Enrique Salem, Partner at Bain Capital, an investor in HYCU, underscores the importance of Simon Taylor’s work, stating, “From the dawn of the digital era to the explosive growth of data and the intricacies of SaaS, our digital world is brimming with both opportunities and threats. Simon Taylor, through this pivotal book, offers not just insights but a roadmap to navigating these challenges. ‘Averting the SaaS Data Apocalypse’ stands as a beacon for businesses, guiding them through the dynamic times of the data revolution. Simon’s profound perspectives offer a blueprint for a more secure and streamlined digital age, ensuring the safeguarding of our digital tomorrow.”

In this compelling narrative, readers are plunged into a journey through the treacherous landscape of SaaS data sprawl. However, amidst the chaos, HYCU emerges as the beacon of hope with its first of its kind, R-Cloud, low code data protection development platform, leading the charge against this digital threat.

“There are 23,000+ SaaS applications in use globally, and more than 50% of successful ransomware attacks happening through SaaS use, and predictions that a successful ransomware attack will occur every two seconds by 2031, signs of the Apocalypse are clear,” said Taylor. “The purpose of the book is to shed light on this emerging crisis, offer practical recommendations on how to deal with it, and learn from some of the most forward-thinking IT leaders that share their experiences in how to truly avert what is becoming the biggest IT challenge of our lifetime.”

Availability:
“Averting the SaaS Data Apocalypse” is available for purchase on Amazon.com in print and Kindle versions worldwide with the pending release in audiobook format on Audible. For special orders, corporate packages, or a free signed copy, please visit: Signed Copy.

###

About Simon Taylor:

Simon Taylor is the CEO and founder of HYCU, the world’s fastest growing multicloud data protection company. He has more than 20 years’ experience in go-to-market strategy development, product marketing and channel sales management for the tech industry. He has worked for leading companies such as Comtrade Group, Forrester Research, Putnam Investments and Omgeo.

He received an MBA in international business from IE (Instituto de Empresa) Business School and an undergraduate degree in operations technology from Northeastern University. He is the author of “John’s Book,” an acclaimed full-length novel, and is a board member at Uncornered, an active member of YPO and a Research Fellow at Boston College.

About HYCU

HYCU is the fastest-growing leader in the multi-cloud and SaaS data protection as a service industry. By bringing true SaaS-based data backup and recovery to on-premises, cloud-native and SaaS environments, the company provides unparalleled data protection, migration, disaster recovery, and ransomware protection to thousands of companies worldwide. As an award-winning and recognized visionary in the industry, HYCU solutions eliminate complexity, risk, and the high cost of legacy-based solutions, providing data protection simplicity to make the world safer. With an industry leading NPS score of 91, customers experience frictionless, cost-effective data protection, anywhere, everywhere. HYCU has raised $140M in VC funding to date and is based in Boston, Mass. Learn more at www.hycu.com.

Attachment

Don Jennings
HYCU, Inc.
617-791-1710
don.jennings@hycu.com

GlobeNewswire Distribution ID 8921609

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)

ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has dosed the first participant with RBI-4000, a self-replicating (srRNA) rabies vaccine, in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.

Curia conducted process development, scale-up and cGMP manufacture of srRNA RBI-4000 drug substance. At approximately 10,000 bases, this srRNA is significantly larger than a conventional linear mRNA and has been historically difficult to manufacture at the scales required for clinical development. Curia’s analytical method development and qualification of the assays were also critical to the release of this srRNA molecule.

“Curia is proud to be a pioneer in manufacturing this new class of srRNA technology by delivering RBI-4000 srRNA drug substance to our partner Replicate in support of their Phase 1 clinical trial,” said Christopher Conway, President, Research & Development, Curia. “We are dedicated to providing advantaged solutions from development to cGMP manufacture for our customers in the mRNA field.”

This new class of srRNA vaccine offers a number of potential improvements to existing mRNA vaccines, including lower dosage requirements and improved tolerability. The advancement also opens the door for further RNA innovation for use in vaccines and therapeutics with fewer constraints on molecule size.

“Our collaboration with Curia helped us manufacture a new class of self-replicating RNAs which have the potential to deliver improved bioactivity, tolerability and efficacy profiles as compared to other RNA technologies,” said Nathaniel Wang, Ph.D., founder and CEO of Replicate. “Curia scaled up a process for longer RNAs that enabled large-scale production at yields, purity and potency to support Replicate’s Phase 1 clinical trial.”

Curia is committed to being a partner of choice from discovery and development through manufacture and commercialization, providing a full suite of services to support small and large molecule, drug substance, drug product aseptic fill-finish and laboratory testing at every phase of the drug development life cycle.

About Curia
Curia, formerly AMRI, is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8920285

Annual Investment Meeting announces new identity as AIM Congress, gears up for 13th edition in Abu Dhabi, May 2024

ABU DHABI, United Arab Emirates, Sept. 13, 2023 (GLOBE NEWSWIRE) — Under its new identity as “AIM Congress,” the Organizing Committee of the World’s Leading Investment Platform will once again gather together regional and international leaders, thinkers, and innovators at the 13th edition of the event taking place from 7 to 9 May 2024 at the Abu Dhabi National Exhibition Centre.

To be anchored on the theme “Adapting to a Shifting Investment Landscape: Harnessing New Potential for Global Economic Development,” AIM Congress 2024 is supported by the Ministry of Industry and Advanced Technology and the Abu Dhabi Department of Economic Development (ADDED) as lead partner.

To be hosted again in the UAE’s vibrant capital, AIM Congress 2024 plans to surpass the success achieved by its last year’s edition which attracted 10,313 participants and 693 speakers from 175 countries.

His Excellency Dr. Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade, expressed his enthusiasm for AIM Congress 2024, stating that, “For more than a decade, AIM Congress has been steadfast in its commitment to promote global economic cooperation and harness the potential of countries especially emerging markets. Amid the backdrop of the shifting global investment scene, it is all-important for countries to adapt and explore new avenues for growth. For its 2024 edition, AIM Congress will continue to be the leading venue where the world’s key economic stakeholders congregate to facilitate dialogue and pave the way for impactful investments that propel a brighter, better future for each and everyone.”

His Excellency Ahmed Jasim Al Zaabi, Chairman of ADDED, said: “Building on the remarkable success of AIM’s previous edition, we are raising the bar to meet the expectations of the global investment community. As the Capital of Capital, Abu Dhabi is leading global conversations on investments outlook and dynamics in an era characterised by mega shifts. Our approach to inward and outward investments is guided by our unwavering commitment to place human development, sustainability, and advanced technology at the core of socio-economic plans at local and international levels, support of ESG agendas, and enhance synergies through international cooperation to improve life for all.”

For his part, Dawood Al Shezawi, President of AIM Global Foundation, commented: “In the face of the various challenges confronting our world today, coupled with the continued decline in global economic growth, emerges the announcement of AIM’s new identity as AIM Congress, which positions itself as a premier venue for investment, providing the optimal platform for esteemed leaders and decision-makers around the world to collectively address our most pressing issues, reshape the global trade and investment landscape, and ultimately foster positive, enduring social and economic impacts in diverse regions worldwide.”

AIM Congress is built upon a foundation of its five key pillars – FDI, FPI, Startups, SMEs, and Future Cities – that underpin the event’s objectives and provide a framework for its activities.

For more details
Shreya Verma – +971 521133926
shreya.verma@aimcongress.com

GlobeNewswire Distribution ID 1000839289

THE PRAX GROUP ANNOUNCES SUCCESSFUL CLOSING OF A US$300 MILLION PRIVATE CREDIT FACILITY

London, Sept. 12, 2023 (GLOBE NEWSWIRE) — The Prax Group (“Prax”) – a British multinational, independent global energy conglomerate dealing in crude oil, petroleum products and biofuels, with a complete integration across the oil value chain, from upstream to midstream and downstream – has announced the successful closing of a new privately placed c.US$300 million (equivalent) Term Loan Facility (the “Facility”).  The Facility achieved a substantial oversubscription and was upsized from an original US$250 million, with four institutions participating in the transaction, including three new lenders.

The Private Credit team at HSBC Bank plc (“HSBC”) acted as Sole Mandated Lead Arranger of the transaction. Funds managed by institutional investors including Chimera Abu Dhabi (“Chimera”) and Orchard Global Asset Management (“Orchard Global”) acted as lenders alongside HSBC.

Ben Lahnstein, Group Chief Financial Officer, Prax, said: “The success of the transaction highlights the confidence our lending groups have in Prax and the depth of our banking and investor relationships. This latest funding has diversified our funding sources and strengthened our balance sheet.  It provides us with a solid financial platform from which to execute future M&A activities, and deliver sustainable, profitable growth.”

The new Facility will be used to refinance the maturing five-year term loan tranche from 2018, as well as for strategic acquisitions.

| ENDS |

Notes to Editors

About The Prax Group: Headquartered in the UK, the Prax Group is a British multinational, independent exploration and production, refining, storage, distribution and sales conglomerate dealing in petroleum products and bio-fuels. The Prax Group has a complete integration across the whole oil value chain, from upstream to midstream and downstream, with offices in London, Houston and Singapore. The Group strives to limit its carbon footprint and to embrace the advent of transitional fuels.

www.prax.com

Corporate Headquarters:
Prax Group
York House
45 Seymour Street
London W1H 7JT
United Kingdom
Email: press@prax.com

Attachments

Prax Group
press@prax.com

GlobeNewswire Distribution ID 8921162

Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference

Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference

Mont-Saint-Guibert, Belgium – September 12, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Cantor Fitzgerald Global Healthcare Conference, which takes place September 26 – 28, 2023 in New York, New York.

Olivier Taelman, Nyxoah’s Chief Executive Officer, will deliver a corporate update on Wednesday, September 27, 2023, at 9:45am EST. A webcast of the presentation will be available on the Events section of Nyxoah’s Investor Relations website. The Company will also be available for 1×1 meetings with institutional investors attending the event.

Nyxoah’s Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

GlobeNewswire Distribution ID 1000839179

FM, Samoa’s Women Minister discuss bilateral ties

Caretaker Foreign Minister Jalil Abbas Jilani met with Samoa’s Minister for Women, Community, and Social Development, Hon Leota Laki Lamositele Sio on the sidelines of the tenth Commonwealth Youth Ministers meeting in London.

Their discussion centered on bolstering cooperation in youth empowerment, with a particular emphasis on advancing opportunities for women.

Source: Radio Pakistan

PML-N always respected, implemented orders of judiciary: Attaullah Tarar

PML-N leader Attaullah Tarar says his party has always respected and implemented the orders of the judiciary.

Talking to the media persons in Islamabad on Wednesday, he said the judgment on Panama Papers case was based on injustice.

He stressed that rule of law is a must to take the country forward on the path of development. He was appreciative of the role played by the lawyers’ community for rule of law in the country.

Source: Radio Pakistan